Riley Bove1, Brain C Healy2, Alexander Musallam3, Pejvak Soltany4, Camilo Diaz-Cruz3, Neda Sattarnezhad3, Bonnie I Glanz1, Pia Kivisäkk5, Karen K Miller6, Tanuja Chitnis1. 1. Partners Multiple Sclerosis Center, Department of Neurology, Brigham and Women's Hospital, Boston, MA, USA/Harvard Medical School, Boston, MA, USA/ Ann Romney Center for Neurologic Disease, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA. 2. Partners Multiple Sclerosis Center, Department of Neurology, Brigham and Women's Hospital, Boston, MA, USA/Harvard Medical School, Boston, MA, USA/Ann Romney Center for Neurologic Disease, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA/Massachusetts General Hospital's Biostatistics Center, Boston, MA, USA. 3. Partners Multiple Sclerosis Center, Department of Neurology, Brigham and Women's Hospital, Boston, MA, USA. 4. Ann Romney Center for Neurologic Disease, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA. 5. Harvard Medical School, Boston, MA, USA/Ann Romney Center for Neurologic Disease, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA. 6. Harvard Medical School, Boston, MA, USA/Neuroendocrine Unit, Massachusetts General Hospital, Boston, MA, USA.
Abstract
BACKGROUND: Increased adiposity is a risk factor for multiple sclerosis (MS) and is associated with increased disability scores. Adipokines may mediate the effects of adiposity on MS disease course. OBJECTIVE: The objective of this study is to examine the association between the adipokines (leptin and fatty acid binding protein-4, FABP4) and clinical course in individuals with MS. METHODS: Subjects (18-65 years) with relapsing-remitting MS or clinically isolated syndrome and <10 year disease duration were selected from a longitudinal clinical study. Cross-sectional and longitudinal models assessed the relationship between two adipokines (leptin and FABP4) and disease severity in women and men, adjusting for age, disease duration and disease type, Vitamin D level, testosterone level, and as well by body mass index (BMI). RESULTS: Mean age of subjects ( N = 163, 56% women) was 39.3 years. Higher FABP4 levels were associated with higher Expanded Disability Status Scale (EDSS) scores in women in both univariate and multivariate analyses (odds ratio: 1.30; p = 0.005). In men, higher FABP4 level was significantly associated with change in EDSS over time (estimate: 0.0062; p = 0.035). We found no association of FABP4 levels with time to next relapse or a measure of processing speed. CONCLUSION: FABP4 levels may be associated with increased disability in both men and women with MS independent of effects of BMI and other hormones. Future studies should expand these analyses and further explore downstream mechanisms of adiposity-related effects in MS.
BACKGROUND: Increased adiposity is a risk factor for multiple sclerosis (MS) and is associated with increased disability scores. Adipokines may mediate the effects of adiposity on MS disease course. OBJECTIVE: The objective of this study is to examine the association between the adipokines (leptin and fatty acid binding protein-4, FABP4) and clinical course in individuals with MS. METHODS: Subjects (18-65 years) with relapsing-remitting MS or clinically isolated syndrome and <10 year disease duration were selected from a longitudinal clinical study. Cross-sectional and longitudinal models assessed the relationship between two adipokines (leptin and FABP4) and disease severity in women and men, adjusting for age, disease duration and disease type, Vitamin D level, testosterone level, and as well by body mass index (BMI). RESULTS: Mean age of subjects ( N = 163, 56% women) was 39.3 years. Higher FABP4 levels were associated with higher Expanded Disability Status Scale (EDSS) scores in women in both univariate and multivariate analyses (odds ratio: 1.30; p = 0.005). In men, higher FABP4 level was significantly associated with change in EDSS over time (estimate: 0.0062; p = 0.035). We found no association of FABP4 levels with time to next relapse or a measure of processing speed. CONCLUSION:FABP4 levels may be associated with increased disability in both men and women with MS independent of effects of BMI and other hormones. Future studies should expand these analyses and further explore downstream mechanisms of adiposity-related effects in MS.
Entities:
Keywords:
Body mass index; fatty acid binding protein; gender; leptin; multiple sclerosis
Authors: A W K Tso; T K Y Lam; A Xu; K H Yiu; H F Tse; L S W Li; L S C Law; B M Y Cheung; R T F Cheung; K S L Lam Journal: Neurology Date: 2011-05-11 Impact factor: 9.910
Authors: Aimin Xu; Annette W K Tso; Bernard M Y Cheung; Yu Wang; Nelson M S Wat; Carol H Y Fong; Dennis C Y Yeung; Edward D Janus; Pak C Sham; Karen S L Lam Journal: Circulation Date: 2007-03-27 Impact factor: 29.690
Authors: Giuseppe Matarese; Pietro Biagio Carrieri; Silvana Montella; Veronica De Rosa; Antonio La Cava Journal: Nat Rev Neurol Date: 2010-07-06 Impact factor: 42.937
Authors: Giuseppe Matarese; Pietro Biagio Carrieri; Antonio La Cava; Francesco Perna; Veronica Sanna; Veronica De Rosa; Daniela Aufiero; Silvia Fontana; Serafino Zappacosta Journal: Proc Natl Acad Sci U S A Date: 2005-03-23 Impact factor: 11.205